Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595887 | 0.92 | PDE9A (0.52) | PDE9AMEN1KMT2AKDM4EOXTR | |
| SCHEMBL3491849 | 0.90 | PDE9A (0.62) | PDE9AMEN1KMT2AKDM4EOXTR | |
| SCHEMBL3595836 | 0.88 | PDE9A (0.51) | PDE9AMEN1KMT2AKDM4EOXTR | |
| SCHEMBL3595181 | 0.87 | PDE9A (0.49) | PDE9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3606050 | 0.87 | PDE9A (0.49) | PDE9AKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL3605996 | 0.86 | PDE9A (0.48) | PDE9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3596869 | 0.86 | PDE9A (0.50) | PDE9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3585753 | 0.86 | PDE9A (0.58) | PDE9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3595669 | 0.85 | PDE9A (0.48) | PDE9AMEN1KMT2AKDM4ERIOK2 | |
| SCHEMBL3492434 | 0.84 | PDE9A (0.64) | PDE9AMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | PDE9A 1/4885MEN1 4034/4885KMT2A 1913/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | PDE9A 1/4885MEN1 4005/4885KMT2A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.